PROALT participates in Anglonordic Life Science Conference 2022

Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council (CSIC) are promising novel biological drugs to treat metastatic colorectal cancer (mCRC) and glioblastoma (GBM). Both could be new options for people whose cancers have not responded to previous lines of treatment. Delegates and Investors at the Anglonordic Life Science Conference [...]

2022-11-10T17:19:26+00:004 May 2022|Tags: |

ProAlt’s COO participates in a discussion panel at Asebio Investor Day 2022

PROTEIN ALTERNTIVES Chief Operating Officer Mr Juan Ignacio Imbaud has participated today in the second discussion panel "Boosting tech transfer in Biotechnology – turning ideas into technological solutions for society" at ASEBIO Investors Day organized by Asociación Española de Bioempresas. The panel was moderated by Carolina Pola, Innovation Strategist at Kaudal, and included reference speakers of the innovation ecosystem [...]

2022-11-10T16:38:18+00:0028 April 2022|Tags: |

PROALT awarded with the Prize for the BEST BIOTECHNOLOGICAL STARTUP

Protein Alternatives SL (PROALT) received the Prize as the BEST BIOTECHNOLOGICAL STARTUP in the first edition of the #startups #awards of LA RAZON. The event was chaired by the Mayor of Madrid José Luis Martínez-Almeida, who was accompanied by Andrés Navarro, CEO of LA RAZÓN and the director Francisco Marhuenda. This first edition of the Sartup Awards has [...]

2022-02-25T12:02:35+00:0024 February 2022|Tags: , , |

ProAlt will attended the 10th International Biotechnology Trade Show BioSpain 2021

September 14th, 2021 ProAlt will be present at BioSpain 2021 from the 29th September to the 1st October and will participate in the one-to-one meetings to present to investors and pharma companies the latest results of its anti-cadherins_RGD therapeutic antibodies in oncology. BioSpain is the 10th International Trade Show & Partnering Event that will take [...]

2021-09-14T13:52:12+00:0014 September 2021|Tags: , |

ProAlt at Swiss Biotech Day in Basel, Switzerland

September 07th, 2021 The Swiss Biotech Day is one of the leading biotechnology conferences in Europe coming back on stage on September 7, 2021 after the worldwide COVID-19 pandemic and will take place at Basel Congress Center. Today, PROALT will present to investors and pharma companies the recent advances with the therapeutic monoclonal antibody PA-0661 [...]

2021-09-14T13:17:13+00:007 September 2021|Tags: , |

ProAlt selected to participate in the EIC Corporate Day with Merck

September 6th, 2021 Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30. Merck, the multinational Healthcare, Life Science [...]

2021-09-14T11:13:12+00:006 September 2021|Tags: , , , |
Go to Top